Nektar Therapeutics Aktie
WKN: 165417 / ISIN: US6402681083
|
18.09.2025 15:39:45
|
Nektar's REZOLVE-AD Phase 2b Study Meets Primary Endpoint In Atopic Dermatitis
(RTTNews) - Nektar Therapeutics (NKTR) Thursday said the REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis met its primary goal.
The REZOLVE-AD study randomized patients with moderate-to-severe atopic dermatitis to receive either rezpegaldesleukin or a placebo. Rezpegaldesleukin demonstrated a statistically significant improvement over placebo on the primary endpoint, the mean change in Eczema Area and Severity Index (EASI) at week 16.
Nektar stock is more than 4% up this morning at $53.60.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!